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Introduction
Heart failure (HF) with preserved ejection fraction (HFpEF) is currently observed in 50% of all HF patients [1, 2] . The incidence of HFpEF increases with age with higher prevalence among women and the most common underlying etiology is hypertensive heart disease [3] [4] [5] . This is in contrast to HF with reduced ejection fraction (HFrEF) which is more prevalent among men and more often due to ischemic heart disease. The prevalence of HFpEF is rising with a rate of 1% per year with no improvement in outcomes when compared with patients with HFrEF [1] . Despite significant advances in the treatment of congestive heart failure (CHF), short-and long-term mortality remains very high. Morbidity and mortality in HFpEF are also similar to values observed in patients with HFrEF [3] . The mortality burden of HFpEF is substantial, ranging from 10% to 30% annually and higher in epidemiological studies than in clinical trials [6] . The aim of this study was to evaluate the clinical characteristics, long-term mortality and to identify prognostic factors in patients hospitalized for acute CHF with left ventricular ejection fraction (LVEF) ≥ 40%.
Methods

Study population
Medical records of consecutive sample of patients hospitalized at the University of Rochester Medical Center for decompensated HF between January 1 st 2003 to May 30 th 2003 with LVEF ≥ 40% were evaluated. Patients were identified using International Classification of Diseases, Ninth revision (ICD9) codes specific for CHF (428.0-428.9) with documented LVEF in the hospital system. The index date was assigned at the first qualifying hospitalization. A detailed review of electronic medical records was carried out to confirm the presentation of decompensated CHF. Clinical demographics and baseline clinical data including history of hypertension, hyperlipidemia, coronary artery disease, prior history of percutaneous coronary intervention or coronary artery bypass graft, diabetes mellitus, and atrial fibrillation (AF) were collected by reviewing the electronic medical records. The electrocardiographic parameters recorded were rate, rhythm, QRS duration, QTc interval, and presence of bundle branch blocks. Use of following medications was recorded: diuretics, beta-blockers, angiotensin converting enzyme inhibitors, angiotensin receptor blocking agents, calcium channel blockers, and digoxin. The laboratory data collected were serum potassium, creatinine, blood urea nitrogen (BUN) and glomerular filtration rate (GFR), calculated using Modification of Diet in Renal Disease equation.
Echocardiographic variables
The echocardiographic variables were retrieved using the hospital electronic database for echocardiograms including: LVEF (%), septal and lateral wall thickness, left atrial diameter, left ventricular end systolic diameter (LVESD), left ventricular end diastolic diameter (LVEDD), pulmonary artery systolic pressure, and left ventricular mass (LVM). All echocardiograms were performed using the American Society of Echocardiography guidelines.
Endpoints
The primary end point for this study was allcause mortality. Mortality data were obtained from Social Security Death Index. The analyses were performed to predict 1-, 3-, and 5-year mortality. The study was approved by the Institutional Review Board.
Statistical analyses
Continuous variables were presented as means and standard deviation while categorical variables were presented as percentages. Comparison of baseline characteristics by mortality status (dead vs. alive) was performed with a t-test for continuous variables and c 2 test for categorical variables. The Cox proportional hazards model with best subset regression was used to determine which clinical and echocardiographic measurements were significantly related to mortality during follow-up of the study. For all echocardiographic variables, patients were divided into quartiles for analyses. For LVEF, a pre-specified cutoff point of 45% was used in the analyses. Where appropriate, Kaplan-Meier cumulative mortality curves were plotted to display trends in mortality over time. All statistical analyses were performed using SAS 9.2 soft ware. A p value < 0.05 was considered statistically significant.
Results
Patient characteristics and follow-up
There were 200 patients identified from the medical records with CHF hospitalization and documented LVEF ≥ 40%. Nine patients were excluded based on findings of moderate to severe valvular disease. Study population was 191 with mean age 70 ± 14.6 years, 115 (60%) female with a mean follow-up of 4.0 ± 2.8 years. The mean LVEF for the cohort was 54 ± 7.4%. One hundred and fortyfive (76%) patients were white. Hypertension was present in 140 (74%), coronary artery disease in 95 (50%), diabetes in 83 (43.7%) and AF in 59 (31%) patients (Table 1) .
Mortality
There were 129 deaths during the follow-up of 4.0 ± 2.8 years. Patients who died in the study follow-up, were older (72.2 ± 13.5 vs. 66.0 ± 15.8, p = 0.010), had higher BUN [mg/dL] (34.7 ± 21.3 vs. 28.3 ± 21.9, p = 0.017) and a trend towards more AF (35% vs. 23%, p = 0.09). There were no differences in other clinical characteristics, laboratory data and use of medications between patients who died vs. alive (Table 1) .
The cumulative 1-year mortality was 25%, 3-year mortality was 41%, and 5-year mortality was 58% (Fig. 1 ). As shown in Figure 2 , there was no www.cardiologyjournal.org difference in mortality between men and women (p = 0.411). Cumulative mortality among patients with history of hypertension vs. no history of hypertension and patients with BUN > 25 mg/dL vs. BUN ≤ 25 mg/dL is shown in Figures 3A and 3B , respetively. There was no difference in mortality Values are given as percentages or means ± standard deviation; ACE-I -angiotensin converting enzyme inhibitor; ARB -angiotensin receptor blocker Figure 1 . Cumulative 1-year mortality was 25%, 3-year mortality was 41% and 5-year mortality was 58%.
among patients with LVEF ≤ 45% and LVEF > 45% (Fig. 4A , p = 0.402). For all the echocardiographic variables presented in Table 2, quartile (Table 3 ). Separate analysis evaluating the risk of mortality, defined as 3-year and 5-year yielded similar results. There was no significant difference in LVM or LV wall thickness between patients with LVEDD > 4.1 vs. ≤ 4.1 cm.
Discussion
Our study confirms that patients admitted with HF with a relatively preserved LVEF are at very high risk for short-and long-term mortality. Few studies have explored the prognostic factors that influence outcomes in this group of patients. Absence of hypertension, BUN > 25 mg/dL, LVEF ≤ 45% and lower LVEDD were identified as important prognostic variables predicting mortality. In addition, the observed high mortality rate was independent of gender.
Hypertension is one of the major risk factors for development of diastolic dysfunction and subsequently HF. There is convincing data to support the statement that adequate control of hypertension decreases the incidence of new onset HF irrespective of the type of anti-hypertensive therapy administered [7] . Hypertension was reported in 74% of our study cohort, which is similar to the prevalence of hypertension in HFpEF reported in the literature. A recent study evaluated sex differences in baseline characteristics and outcomes in 4,128 patients enrolled in Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial [8] . Hypertension was associated with a lower all-cause mortality (HR = = 0.845) among women, however the p value did not reach statistical significance (0.138). Overall better prognosis seen in patients with hypertension could be explained by several mechanisms. Underlying etiologic mechanisms leading to diastolic HF other than hypertension, for example coronary artery disease and diabetes mellitus might be one of the reasons leading to higher mortality. As shown in a study by O'Connor et al. [9] , the coronary artery disease index and diabetes mellitus were associated www.cardiologyjournal.org with increased mortality in patients with HF and LVEF > 45%. Furthermore, anti-hypertensive therapy for patients with hypertension may have resulted in the observed protective effect [7] .
The association between abnormal renal function and increased risk of death and hospitalization in HF patients has previously been reported [10, 11] . A post-hoc analysis of the Digitalis Investigation Group (DIG) trial demonstrated increasing mortality with decreasing quartile of creatinine clearance and 6-min walking distance < 262 m [12] . Similarly, a post-hoc analysis of the Studies Of Left Ventricular Dysfunction (SOLVD) registry demonstrated worse combined outcome of hospitalization or death for the subset of patients with creatinine clearance < 60 mL/min [13] . Impaired renal function represents advanced underlying HF and systemic disease whether it is hypertension, diabetes, or vascular disease resulting in high risk of mortality.
LVEF is a widely used clinical measure to assess left ventricular function and has been shown to predict mortality in HF patients with low ejection fraction (EF) [14] . The relationship between a wide range of LVEF and both fatal and non-fatal outcomes was assessed in 7,599 patients enrolled www.cardiologyjournal.org in the CHARM (Candesartan in Heart Failure--Assessment of Reduction in Mortality) study population [15] . The mean LVEF was 38.8 ± 14.9%. The study concluded that LVEF predicts mortality with overall better survival in patients with increasing EF up to 45%. For each 10% reduction in the EF below 45%, the risk for total mortality increased by up to 39%.
The role of left ventricle cavity size as a prognostic factor is well studied in patients with systolic HF. In a small sample of 50 patients with CHF with mean LVEF 32%, LVEDD (6.1 cm) was not associated with increased mortality [16] . However, in the same study, the LVESD (4.7 cm) was significantly associated with higher mortality. In this study, patients with preserved LVEF were Table 3 . Cox regression models for entire follow-up, 1-year, 3-year, and 5-year.
Parameter
Hazard ratio 95% hazard ratio confidence limits P The following variables were entered in the model: atrial fibrillation, age > 75 years, BUN > 25, history of coronary artery bypass grafting, history of coronary artery disease, hypertension, hyperlipidemia, hematocrit, LVEDD, LVEDD (high risk quartile), LVEF > 50%, LVEF < 45%, LVEDD < 4.1 cm; BUN -blood urea nitrogen; LVEDD -left ventricular end diastolic dimension; LVEF -left ventricular ejection fraction We did not find age and AF as significant predictors of mortality independent of other covariates. This could be a result of small sample size. Other studies have shown age as one of the significant determinants of prognosis in patients with HFpEF [19] . The approximate 5-year mortality in patients with HFpEF rises with increasing age from 15% in patients < 50 years to 33% in patients with age 50-70 years and approaching 50% in patients > 70 years old [19] . In our study, patients were relatively older (70.2 ± 14.6) and influence of age on mortality could not be demonstrated. AF is common among patients with HFpEF and it was reported in 31% patients in our study. CHARM sub-group analysis showed that patients with AF and preserved LVEF had higher risk for adverse cardiovascular outcome (34% with cardiovascular death or CHF hospitalization) relative to those with preserved LVEF and sinus rhythm (21%) [20] . After covariate adjustment, AF at baseline remained an independent predictor of all-cause mortality regardless of baseline LVEF. However, another report showed that AF was associated with an excessive mortality mainly related to the advanced age [21] . An explanation for variable results regarding prognostic significance of AF in HFpEF might be due to the differences in the study population. Alternatively, loss of atrial kick during AF may result in different hemodynamic effects among the patients with LVEF > 50% as compared with those with slightly reduced LVEF 40-50%.
Limitations of the study
Our study has limitations, including the retrospective design and the small study cohort. We also lacked detailed systematic examination of the diastolic dysfunction in each patient and biomarkers such as troponin and B-type natriuretic peptide level. Neither the data on revascularization during the index hospitalization were analyzed. Further studies involving larger patient populations with detailed information on diastolic dysfunction are required to elucidate the validity of our clinical findings.
Conclusions
Mortality among patients hospitalized for HF with LVEF ≥ 40% remains very high. Prognosis of patients hospitalized for HF with LVEF ≤ 45% is as poor as the prognosis of HF patients with LVEF > 45%. Absence of hypertension and elevated BUN indicate increased risk of short-and long-term mortality. Patients hospitalized for HF with absence of hypertension need special care to improve their outcomes. LVEDD is found to be an independent predictor of mortality in HF patients with LVEF ≥ 40%. A lower LVEDD may represent a "stiff" ventricle with compromised diastolic heart function.
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